Upload
others
View
7
Download
0
Embed Size (px)
Citation preview
DESIGN A POSTER PRESENTATION
MONIQUE BOUVIER, PHD, RN, PNP-BC
RESEARCH SCIENTIST
STANFORD HEALTH CARE
DISSEMINATION WEBINAR SERIES
RECORDING AVAILABLE REGISTER NOWTODAY’S WEBINAR
REGISTER FOR HEALTHCARE CON
HEALTHCARE CON PRECONFERENCE
PURPOSE OF THE POSTER
• Inform people about your project visually
• Creatively showcase all the hard work you have done
• Start a conversation
https://www.neurologytimes.com/blogs/drugs-and-creativity-fact-or-fiction
https://www.neurologytimes.com/blogs/drugs-and-creativity-fact-or-fiction
MOVIE POSTERS
YOU HAVE 5 SECONDS
STEPS TO POSTER MAKING
• Audience
• Content planning
• Layout development
• System for development
• Focus on the details
• Printing considerations
• Practice speaking to it
STEP 1: WHO IS YOUR AUDIENCE?
VS
STEP 2: PLANNING YOUR CONTENT
• What is the main take away from your project? • What is interesting about your project?• Think about the steps you took to discover the above information
• How can you visually display that?
• Turn words into pictures
• Keep it simple • Aim for 1000 words or less
STEP 3: LAYOUT • Read conference poster presentation instructions to determine layout
• Sketch it out• White space is good to have
• Figure out the flow to best convey your project’s key messages• Use your abstract as a guide
• Most common type of format is the column format
Photo credit: https://ebiinterfaces.wordpress.com/2016/03/11/designing-our-vizbi-2016-conference-poster/
https://ebiinterfaces.wordpress.com/2016/03/11/designing-our-vizbi-2016-conference-poster/
STEP 3: LAYOUT CONT.
Headings
• Research: Introduction, Aim/ Purpose, Methods, Results, Conclusion/ Discussion • Other headings: Nursing implications, Future Direction, Theoretical Framework, Limitations
• Evidence-Based Practice: Introduction, Objectives, Methods/ Process of Implementation, Results, Implications to Practice/ Conclusions
• Other headings: Recommendations, EBP Model, Limitations
• Quality Improvement: Introduction, Statement of Problem, Methodology/ Implementation, Results, Outcomes
• Other headings: Education, Strategy, Limitations, Discussion, Case Description
• Works in Progress: Introduction, Background, Problem, Methodology- further delineate, Anticipated Findings
POSTER PRESENTATION
Author Names and Titles HereDepartment Affiliations Here, Stanford Health Care, Stanford, California
Insert Poster Title Here
Introduction
• Check with conference organizers for the specifications for poster size and orientation (e.g., maximum poster size; landscape, portrait, or square).
• The page size of this poster template is 39” x 20” landscape format. Print this poster at 200%. The final size will be 78” x 40.”
•Use Helvetica for title and body text.
• This slide is half the size of the final poster. Therefore 22 point font will print at 44 points.
Methods
Conclusion
Results
Cited Literature• One Potato• Two Potato• Three Potato• Four
Acknowledgments• One Potato• Two Potato• Three Potato• Four
Author Names and Titles Here
Department Affiliations Here, Stanford Health Care, Stanford, California
Insert Poster Title Here
Introduction
Check with conference organizers for the specifications for poster size and orientation (e.g., maximum poster size; landscape, portrait, or square).
The page size of this poster template is 39” x 20” landscape format. Print this poster at 200%. The final size will be 78” x 40.”
Use Helvetica for title and body text.
This slide is half the size of the final poster. Therefore 22 point font will print at 44 points.
Methods
Conclusion
Results
Cited Literature
One Potato
Two Potato
Three Potato
Four
Acknowledgments
One Potato
Two Potato
Three Potato
Four
• Keep in bullet form
• Provide a high-level overview of activities
• Only those relevant to the attendee to understand what you have undertaken
PRINTING• Slide is 24W x 40H• Check your conference information and adjust as
needed
Short Pertinent Title of StudyAuthors Listed with note to affiliation below: E.V. Smith1, L.Z. Bear2
Only qualifying authors should be listed [see link for guidance] http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html
RESULTS
METHODS
OBJECTIVE
BACKGROUND• Introductory statement about phenomenon• Why this is important to clinicians• What is known about this problem• What is the gap in knowledge
Clear statement on what you set out to achieve
Table 1. Keep it relevant and progress the reader through your presentation.
RESULTS
1Patient Care Services, Stanford Health Care; 2Stanford University School of Medicine, Stanford, CA,
CONCLUSION• Primary and secondary findings• Why this is important• Implications and recommendations for clinical practice.• Be sure conclusion addresses your objective!
References:Funded by disclosure1. References in a format that is acceptable for the scientific society. 2. Guy, Great (2022). How to excel at poster presentations. Journal of Unicorns. 2014 2(4): 357-357.
Acknowledgments:K li it d t l th i t ib t t ti th hi
• Start with describing your sample
• Ensure results are addressing your objective
• Do not interpret results in this section
• Provide test and confidence intervals where necessary
Figure 1. Depict results visually and provide enough data for interpretation
0
20
40
60
80
100
120
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022
Fictional Quality Measure
Patients HAC
Results are King - Use Smart Graphics
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Univariate Multivariate
Unstandardized b 95% CI Unstandardized Standardized b 95% CI
Variable Operation b Coefficient Lower Upper P Value b Coefficient B Coefficient Lower Upper P Value
Age 60+y v
STEP 4: SYSTEM TO USE • Read what size the poster needs to be
• HCC: 36” (width) by 42” (height)
• Design -> Slide Size -> Custom Slide size -> insert dimensions
STEP 5: THE DETAILS
• Keep title short: no more than 2 lines • Use upper and lower case letters
• Boxes vs no boxes • Regardless keep information lined up (use grid lines)
• Color• Keep a color scheme (limit 2-3 colors)
• Do not use an image in the background
• Black on white easiest to read
STEP 5: THE DETAILS CONT.
• Bulleted text or 1-2 sentence paragraphs • Fonts
• Use serif fonts not script or comic sans or other fonts we are not used to reading • Want to be able to read from 5 feet away
• Font size guidelines (minimums):• Title- 90 pt
• Authors- 48 pt
• Headings- 36 pt
• Text- 24 pt
• Captions- 18 pt
STEP 5: THE DETAILS CONT.
• Images• High quality necessary
• Do not use unnecessary pictures
• Caption all charts and graphs
• Keep images simple
• Branding• Conference
• Institutional
• Company
• Grant
RCT Evaluating Optimal Patient Turning for Reducing Hospital Acquired Pressure Ulcers: Preliminary Results of the LS-HAPU Study.
Pickham, D., Ballew, B., Duhon, P., Mayer, B.
• Hospital Acquired Pressure Injuries (HAPI) are insidious multi-factorial complications arising from periods of inactivity
• Patient’s with HAPI have
• 3x longer LOS
• 4x increase in hospital mortality
• 503,000 related hospitalizations per year
• Costs = $11 billion/year
• Two Cochrane reviews address benefits of repositioning
• “repositioning is an integral component of pressure ulcer prevention and treatment…(there are a) lack of robust evaluations of frequency and position…(and therefore) great uncertainty remains”.
Conduct pragmatic RCT investigating the effect of optimal patient care procedures (repositioning every 2 hours with at least 15 minutes of tissue depressurization), supported by use a patient sensor and novel quantitative measures, in preventing HAPI in acutely ill subjects
An investigator-initiated pragmatic, single site, open label, two arm, parallel, randomized controlled trial with one-to-one group allocation
Treatment: Providing optimal care, supported by data derived from a wearable patient sensor (Leaf Healthcare, Inc., Pleasanton, CA) (simulated user dashboard shown)
Control: Providing usual care, without the aid of data, initiated by usual nursing practice
• Adults >18 years• Admitted to an ICU• No adhesive sensitivity/allergies
• Single site, Academic Medical Center• Unit A – 25 bed post cardiothoracic surgery• Unit B – 33 bed medical, surgical, trauma
Assessed for eligibility (n=1564)
Excluded (n=237) - Documented (n=49) - Not Documented (n=202)
Randomized (n=1313 )
Enrollment
Allocated to control (n=653) - Received allocated intervention (n=571) - Did not receive allocated intervention (n=82) - Due to:
No data n=22Misallocation n=54Multiple group assignment n=1
Allocated to treatment (n=660) - Received allocated intervention (n=633) - Did not receive allocated intervention (n=27) - Due to:
No data n=22Misallocation n=4Multiple group assignment n=1
Analyzed (n=555) - Added to analysis (n=2, crossover) - Excluded from analysis (n=18)
- Less than 2hrs monitoring time
Analyzed (n=671) - Added to analysis (n=49, crossover) - Excluded from analysis (n=11)
-Less than 2hrs monitoring time
Allocation
AnalysisN=1226
Wearable Patient Sensor Communication Network
Location of Patient Monitoring Sensor
Intervention group provided care with the aid of monitoring dashboard
A
Arrival
Medical
Surgical
T
C
T
C
B
Medical
Surgical
T
C
T
C
Treatment
Control
Characteristics Control Treatment Total Patient DemographicsMale, No./Total No. (%) 302/555 (54.4) 373/671 (55.6) 675/1226 (55.1)Age, mean (SD), yr 60.1 (17.9) 59.8 (16.9) 60 (17.3)Race, No./Total No. (%)
White 300/555 (54.1) 361/671 (53.8) 661/1226 (53.9)Black or African American 35/555 (6.3) 31/671 (4.6) 66/1226 (5.4)Asian 87/555 (15.7) 95/671 (14.2) 182/1226 (14.8)
Ethnicity, No./Total No. (%)Hispanic/Latino 82/555 (14.8) 113/671 (16.8) 195/1226 (15.9)Non-Hispanic/Latino 458/555 (82.5) 538/671 (80.2) 996/1226 (81.2)
Body Mass Index, mean (SD) 23.3 (5.7) 23.6 (5.9) 23.5 (5.8)Clinical Indices
Charlson Comorbidity Index, mean (SD) 3.7 (3.3) 3.8 (3.3) 3.8 (3.3)Apache II Score, mean (SD) 13 (6.9) 13.6 (7.0) 13.4 (6.9)Nursing Acuity Index, mean (SD) 64.9 (30.3) 65.1 (30.3) 65 (30.3)Glasgow Coma Scale, mean (SD) 12.5 (3.9) 12.2 (4) 12.4 (4)ASA Risk Score at 1st Surgery, mean (SD) 3.3 (0.7) 3.2 (0.7) 3.2 (0.7)
Temperature, mean (SD), F° 96.7 (5.4 96.7 (4.9) 96.7 (5.2)Ventilator Use Smoking History, mean (SD), yr 20.6 (15.2) 20.7 (14.7) 20.7 (14.9)Diabetes, No./Total No. (%) 127/555 (22.9) 151/671 (22.5) 278/1226 (22.7)Laboratory Blood Values
White Blood Cell, mean (SD), k/Ul ^ 11.2 (6) 12 (10.7) 11.6 (8.9)Glucose, mean (SD), mg/dL ^ 133.3 (55.6) 138.8 (66.3) 136.3 (61.7)Hemoglobin, mean (SD), mg/dL ^ 12.1 (2.2) 12 (2.3) 12 (2.2)Albumin, mean (SD), ^ 3.1 (0.7) 3.1 (0.7) 3.1 (0.7)Lactate, mean (SD), * 3.9 (3) 4.1 (3.2) 4 (3)
Drugs AdministeredAnticoagulants, No./Total No. (%) 400/555 (72.1) 485/671 (72.3) 885/1226 (72.2)Antibiotic, No./Total No. (%) 409/555 (73.7) 501/671 (74.7) 910/1226 (74.2)Insulin, No./Total No. (%) 294/555 (53) 349/671 (52) 643/1226 (52.4)Sedative, No./Total No. (%) 455/555 (82) 539/671 (80.3) 994/1226 (81.1)Steroid, No./Total No. (%) 250/555 (45) 282/671 (42) 532/1226 (43.4)Vasopressor, No./Total No. (%) 511/555 (91.1) 617/671 (92) 1128/1226 (92)
ICU MonitoringUnit A, No./Total No. (%) 190/555 (34.2) 237/671 (35.2) 427/1226 (34.8)Type of Admission No./total No. (%)
Medical 208/555 (37) 247/671 (37) 455/1226 (37)Surgery 347/555 (63) 423/671 (63) 770/1226 (63)
Monitoring Time, mean (SD), hours 80.9 (132.6) 86.6 (127) 84 (129.5)
*Treatment and control groups are equivalent for all variables (p>0.05). ^On day 1 of admission to ICU. *Highest during hospital admission. °Maximum temperature during ICU stay.
- Compliance to turning increased by approximately 40% in the treatment group
- Significant differences exist in compliance across nursing shifts
- 5 fold difference in the incidence of HAPI between treatment and control groups.
This study found a significant difference in the incidence of HAPI between groups. Study analyses is ongoing to further validate these findings.
Trial is registered with ClinicalTrials.gov, NCT02533726.
This study is co-funded by Stanford Health Care and Leaf Healthcare, Inc. Competing Interests: Leaf Healthcare, Inc. was co-founded by Barrett Larson MD, a physician employed at Stanford University. Leaf Healthcare, Inc. is a co-sponsor of this study and provides monitoring hardware, proprietary software and technical support.
Percentage of time in patient position for treatment (green) and control groups
Bullet PointsHeadings
Graphs and pictures are preferred
RCT Evaluating Optimal Patient Turning for Reducing Hospital Acquired Pressure Ulcers: Preliminary Results of the LS-HAPU Study.
Pickham, D., Ballew, B., Duhon, P., Mayer, B.
Introduction
Aim
Study Design
Hospital Acquired Pressure Injuries (HAPI) are insidious multi-factorial complications arising from periods of inactivity
Patient’s with HAPI have
3x longer LOS
4x increase in hospital mortality
503,000 related hospitalizations per year
Costs = $11 billion/year
Two Cochrane reviews address benefits of repositioning
“repositioning is an integral component of pressure ulcer prevention and treatment…(there are a) lack of robust evaluations of frequency and position…(and therefore) great uncertainty remains”.
Conduct pragmatic RCT investigating the effect of optimal patient care procedures (repositioning every 2 hours with at least 15 minutes of tissue depressurization), supported by use a patient sensor and novel quantitative measures, in preventing HAPI in acutely ill subjects
An investigator-initiated pragmatic, single site, open label, two arm, parallel, randomized controlled trial with one-to-one group allocation
Treatment: Providing optimal care, supported by data derived from a wearable patient sensor (Leaf Healthcare, Inc., Pleasanton, CA) (simulated user dashboard shown)
Control: Providing usual care, without the aid of data, initiated by usual nursing practice
Participants
Setting
Adults >18 years
Admitted to an ICU
No adhesive sensitivity/allergies
Single site, Academic Medical Center
Unit A – 25 bed post cardiothoracic surgery
Unit B – 33 bed medical, surgical, trauma
Intervention
Wearable Patient Sensor Communication Network
Location of Patient Monitoring Sensor
Intervention group provided care with the aid of monitoring dashboard
Randomization
Results – Enrollment
Baseline Demographic and Clinical Data
CharacteristicsControl Treatment Total
Patient Demographics
Male, No./Total No. (%)302/555 (54.4)373/671 (55.6)675/1226 (55.1)
Age, mean (SD), yr60.1 (17.9)59.8 (16.9)60 (17.3)
Race, No./Total No. (%)
White300/555 (54.1)361/671 (53.8)661/1226 (53.9)
Black or African American35/555 (6.3)31/671 (4.6)66/1226 (5.4)
Asian87/555 (15.7)95/671 (14.2)182/1226 (14.8)
Ethnicity, No./Total No. (%)
Hispanic/Latino82/555 (14.8)113/671 (16.8)195/1226 (15.9)
Non-Hispanic/Latino 458/555 (82.5)538/671 (80.2)996/1226 (81.2)
Body Mass Index, mean (SD)23.3 (5.7)23.6 (5.9)23.5 (5.8)
Clinical Indices
Charlson Comorbidity Index, mean (SD)3.7 (3.3)3.8 (3.3)3.8 (3.3)
Apache II Score, mean (SD)13 (6.9)13.6 (7.0)13.4 (6.9)
Nursing Acuity Index, mean (SD)64.9 (30.3)65.1 (30.3)65 (30.3)
Glasgow Coma Scale, mean (SD)12.5 (3.9)12.2 (4)12.4 (4)
ASA Risk Score at 1st Surgery, mean (SD)3.3 (0.7)3.2 (0.7)3.2 (0.7)
Temperature, mean (SD), F96.7 (5.496.7 (4.9)96.7 (5.2)
Ventilator Use
Smoking History, mean (SD), yr20.6 (15.2)20.7 (14.7)20.7 (14.9)
Diabetes, No./Total No. (%)127/555 (22.9)151/671 (22.5)278/1226 (22.7)
Laboratory Blood Values
White Blood Cell, mean (SD), k/Ul ^11.2 (6)12 (10.7)11.6 (8.9)
Glucose, mean (SD), mg/dL ^133.3 (55.6)138.8 (66.3)136.3 (61.7)
Hemoglobin, mean (SD), mg/dL ^ 12.1 (2.2)12 (2.3)12 (2.2)
Albumin, mean (SD), ^3.1 (0.7)3.1 (0.7)3.1 (0.7)
Lactate, mean (SD), *3.9 (3)4.1 (3.2)4 (3)
Drugs Administered
Anticoagulants, No./Total No. (%)400/555 (72.1)485/671 (72.3)885/1226 (72.2)
Antibiotic, No./Total No. (%)409/555 (73.7)501/671 (74.7)910/1226 (74.2)
Insulin, No./Total No. (%)294/555 (53)349/671 (52)643/1226 (52.4)
Sedative, No./Total No. (%) 455/555 (82)539/671 (80.3)994/1226 (81.1)
Steroid, No./Total No. (%)250/555 (45)282/671 (42)532/1226 (43.4)
Vasopressor, No./Total No. (%)511/555 (91.1)617/671 (92)1128/1226 (92)
ICU Monitoring
Unit A, No./Total No. (%)190/555 (34.2)237/671 (35.2)427/1226 (34.8)
Type of Admission No./total No. (%)
Medical 208/555 (37)247/671 (37)455/1226 (37)
Surgery347/555 (63)423/671 (63)770/1226 (63)
Monitoring Time, mean (SD), hours80.9 (132.6)86.6 (127)84 (129.5)
*Treatment and control groups are equivalent for all variables (p>0.05). ^On day 1 of admission to ICU. *Highest during hospital admission. Maximum temperature during ICU stay.
Patient Positioning
Turning Compliance
HAPI Incidence
Conclusions
Compliance to turning increased by approximately 40% in the treatment group
Significant differences exist in compliance across nursing shifts
5 fold difference in the incidence of HAPI between treatment and control groups.
This study found a significant difference in the incidence of HAPI between groups. Study analyses is ongoing to further validate these findings.
Trial is registered with ClinicalTrials.gov, NCT02533726.
This study is co-funded by Stanford Health Care and Leaf Healthcare, Inc.
Competing Interests: Leaf Healthcare, Inc. was co-founded by Barrett Larson MD, a physician employed at Stanford University. Leaf Healthcare, Inc. is a co-sponsor of this study and provides monitoring hardware, proprietary software and technical support.
Disclosures
Percentage of time in patient position for treatment (green) and control groups
A
Arrival
Medical
Surgical
T
C
T
C
B
Medical
Surgical
T
C
T
C
Treatment
Control
Assessed for eligibility (n=1564)
Excluded (n=237)
-Documented (n=49)
-Not Documented (n=202)
Randomized (n=1313 )
Enrollment
Allocated to control (n=653)
-Received allocated intervention (n=571)
-Did not receive allocated intervention (n=82)
-Due to:
No data n=22
Misallocation n=54
Multiple group assignment n=1
Allocated to treatment (n=660)
-Received allocated intervention (n=633)
-Did not receive allocated intervention (n=27)
-Due to:
No data n=22
Misallocation n=4
Multiple group assignment n=1
Analyzed (n=555)
-Added to analysis (n=2, crossover)
-Excluded from analysis (n=18)
-Less than 2hrs monitoring time
Analyzed (n=671)
-Added to analysis (n=49, crossover)
-Excluded from analysis (n=11)
-Less than 2hrs monitoring time
Allocation
Analysis
N=1226
Pleasing from a distance
Acknowledge all authors/institutions
Avoid blocked text
Pay attention to branding
STEP 6: PRINTING AND ADDITIONAL MATERIALS
• Save slide in .pdf format before printing
• Cloth vs paper
• Print slide fitting it to one page to confirm the layout
• Handouts are a nice touch
• Be creative with how you are displaying
STEP 7: PRACTICE PRACTICE PRACTICE
Speed dating vs poster presentation
EVOLVING POSTER PRESENTATIONS
https://www.insidehighered.com/news/2019/06/24/theres-movement-better-scientific-posters-are-they-really-better
https://www.insidehighered.com/news/2019/06/24/theres-movement-better-scientific-posters-are-they-really-better
PROOF-READING/ EDITING A NECESSITY!
THANKS!
• Monique Bouvier• [email protected]• [email protected]
mailto:[email protected]
Design a Poster presentationDissemination webinar series Register for healthcare conHealthcare con preconference Purpose of the poster Movie postersYou have 5 seconds Slide Number 8Steps to Poster making Step 1: Who is your audience?Step 2: Planning your contentStep 3: Layout Step 3: Layout cont.Poster Presentation Slide Number 15Step 4: System to use Step 5: The detailsStep 5: The details cont. Step 5: The Details cont. Slide Number 20Slide Number 21Step 6: Printing and additional materialsStep 7: practice practice practice Evolving poster presentations Proof-reading/ Editing Thanks!